Ebola and Marburg Vaccines: First Steps

Two investigational DNA vaccines — one encoding Ebola virus Zaire and Sudan glycoproteins, and the other, Marburg virus glycoprotein — were safe and immunogenic in an African population.

The continuing Ebola epidemic in Africa lends urgency to the need for a vaccine. In a phase IB, double-blind, placebo-controlled trial conducted in Uganda, investigators assessed the safety and immunogenicity of two DNA vaccines: one encoding Ebola virus glycoproteins (Zaire — the species causing the current outbreak — and Sudan), and the other, Marburg virus glycoprotein. The 108 trial participants (aged 19–45, predominantly men) were randomized to receive Ebola vaccine only, Marburg vaccine only, both vaccines together (one in each arm), or saline placebo at 0, 4, and 8 weeks.

Both vaccines were well tolerated; local and systemic adverse events were similar between vaccine and placebo recipients.

Four weeks after dose three, vaccine-induced…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Ebola and Marburg Vaccines: First Steps

Topics

Reviewing Author